CAPR logo

CAPRICOR THERAPEUTICS INC

CAPRNASDAQ
🏆 #2982 by market capEarnings Nov 9US Equity
$8.58▼ $0.11 (−1.32%)
Market closed · at close
🔔
Track CAPR
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.3%
7d▼ 1.2%
14d▲ 0.2%
30d▼ 13.4%
ytd▼ 70.3%
1y▲ 19.3%
🏦Market Cap
$493M
Small Cap
📈Revenue Growth (YoY)
-100.0%
Declining
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak

Trading Snapshot

Day Range
$8.45 – $8.69
52-Week Range
$2.96 – $40.37
Volume
$2.91B
Avg Volume
$3.63B
Shares Outstanding
57.5M
Next Earnings
Oct 25, 2026

Fundamentals Snapshot

Annual Revenue
$75M
Last Q Revenue
$19M
P/E Ratio
-3.5
P/S Ratio
0.0x
EPS (TTM)
$-2.23
Dividend Yield
0.00%

Why Investors Own CAPR

  • ✓High-growth profile — revenue up -9.5% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 75% gross margin and 18% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CAPR logo

CAPRICOR THERAPEUTICS INC

CAPR
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$75M▼ −8.6% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
75.4%▲ +2.6% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$19M▼ −8.6% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$14M▼ −8.6% YoY
StockOtter · stockotter.space

About CAPRICOR THERAPEUTICS INC

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Ratings

ⓘ
Consensus
Buy
16 analysts
Strong Buy3
Buy4
Hold9
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
Barron’s·2h ago

CAPRICOR THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift CAPR price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

CAPRICOR THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.